Piergiorgio Messa

Piergiorgio Messa appears in the volume as a nephrologist whose work anchors its discussion of hepatitis C-related liver disease in patients receiving long-term dialysis. He is listed as a contributor from Milan and as a member of the Division of Nephrology and Dialysis at Maggiore Hospital, IRCCS Foundation, in Milan, Italy. His contribution is presented alongside those of Fabrizio Fabrizi, Vivek Dixit, and Paul Martin, linking renal and hepatological expertise in a field where viral infection cannot be reduced to a liver disorder alone.

Identity and Professional Setting

Piergiorgio Messa’s documented identity is institutional as well as individual. The book places him within the nephrology and dialysis service of Maggiore Hospital, IRCCS Foundation, Milan, while his co-authors Fabrizio Fabrizi and Paul Martin are associated with hepatology at the University of Miami and Vivek Dixit with the same medical school. This arrangement establishes the chapter’s cross-disciplinary standpoint: dialysis patients are considered simultaneously as people with chronic kidney disease, possible hepatic injury, systemic viral disease, and competing treatment risks.

The volume’s broader preface explains why such a perspective is necessary. Hepatitis C virus infection is described as a systemic disease capable of affecting the liver while also inducing autoimmune, dermatological, and renal disease. The book therefore treats infection as a major nephrology, dialysis, and transplantation concern, rather than as an isolated hepatology topic. Messa’s placement within the dialysis chapter gives him a defined role in that larger intellectual architecture: he represents the renal-care setting in which infection, comorbidity, surveillance, and treatment decisions converge.

Contribution to the Dialysis Chapter

Messa is credited as one of the authors of “Hepatitis C-Related Liver Disease in Dialysis Patients,” a chapter devoted to the available evidence on liver disease among people undergoing long-term dialysis. Its stated purpose is to review the recent evidence concerning hepatitis C-related liver injury in this population, after transmission had already been reduced in developed countries through serologic screening of blood, routine erythropoietin use for anemia and chronic kidney disease, and infection-control procedures within dialysis units.

The chapter’s subject is clinically difficult because liver disease is often quiet in dialysis patients. Hepatitis C-related disease is described as mostly asymptomatic, while fatigue, asthenia, and cognitive impairment may occur in dialysis patients regardless of their serologic status. The authors nevertheless identify biochemical signals, including frequent elevations of serum transaminases and gamma-glutamyl transpeptidase in infected patients. In a large United States cohort of 13,664 long-term dialysis patients, anti-HCV seropositivity was independently associated with serum alkaline-phosphatase activity after adjustment for several covariates, including surrogates of malnutrition-inflammatory complex syndrome.

Messa’s chapter also records a further laboratory distinction: HCV-infected dialysis patients had higher serum intact parathyroid hormone levels than comparison patients, 422 ± 423 versus 338 ± 356 pg/ml, with the difference persisting among African-American patients. These observations were linked to hepatic osteodystrophy, a complication described in people with hepatitis outside dialysis. Yet the chapter emphasizes why such abnormalities can be overlooked: dialysis patients commonly have arterial hypertension, gastrointestinal bleeding, anemia, vascular-access failure, and other competing conditions. In this setting, a modest biochemical change may be clinically real but easily absorbed into the background noise of chronic renal disease.

Clinical and Epidemiological Significance

The evidence associated with Messa’s contribution places hepatitis C within a changing dialysis environment. After the identification of hepatitis C virus as the main cause of non-A, non-B hepatitis in 1989, the epidemiology of infection in hemodialysis patients changed substantially. Early high prevalence reflected both the former burden of transfusion-related infection and continuing concern about nosocomial transmission inside dialysis units. Improved blood-donor screening and the widespread use of erythropoiesis-stimulating agents reduced the need for transfusions, while infection-control procedures helped reduce transmission in developed countries.

The chapter does not portray reduced transmission as the disappearance of the problem. Hepatitis C remained the most frequently recognized cause of liver damage in patients with chronic kidney disease, and the book’s wider epidemiological account estimates that roughly 170 million people worldwide were infected, corresponding to an estimated prevalence of 3 percent. Diagnosis depends on separating exposure from active disease: anti-HCV antibodies detected by third-generation enzyme-linked immunosorbent assays establish serologic evidence, whereas detectable HCV RNA identifies active infection. Chronic infection requires both anti-HCV and HCV RNA positivity, with molecular assays having a threshold of approximately 15 IU/ml.

This distinction matters for the population Messa studies. A dialysis patient may carry evidence of prior exposure without ongoing viremia, or may have active infection whose clinical expression is obscured by renal comorbidity. Evaluation therefore has to include both hepatic and extrahepatic impact. Liver injury can be assessed by biopsy or by noninvasive measures such as biochemical fibrosis scores and FibroScan elastometry, while systemic consequences include cryoglobulinemia-associated vasculitis and renal disease. Hepatitis C is identified as the major cause of mixed cryoglobulinemia, a vasculitis that may involve arthralgia, arthritis, Raynaud phenomena, purpura, peripheral neuropathy, low complement levels, and kidney disease.

Treatment, Toxicity, and Patient Experience

Messa’s clinical context also intersects with the volume’s account of antiviral treatment. In the treatment landscape described for 2011, therapy was based mainly on pegylated interferon and ribavirin, with a protease-inhibitor triple regimen of telaprevir or boceprevir, pegylated interferon, and ribavirin for genotype 1 infection. Pegylated interferon and ribavirin achieved a sustained virologic response in more than half of patients with chronic infection, while first-generation protease inhibitors increased response rates among genotype 1 patients by approximately 20 to 30 percent. The promise of treatment was therefore substantial, but its practical burden remained decisive for people already living with end-stage renal disease and dialysis.

The volume identifies treatment toxicity as a major obstacle. Interferon-associated adverse effects include flu-like symptoms such as fever, fatigue, headache, myalgia, and arthralgia; hematologic complications such as anemia and neutropenia; and neuropsychiatric effects including depression and anxiety. These effects led to dose reduction in 35–42 percent of treated patients and discontinuation in approximately 30 percent. The treatment question consequently extends beyond viral clearance or liver histology: it also concerns whether a patient can tolerate a demanding regimen without further undermining daily functioning and quality of life.

The dialysis chapter connects infection with that experiential dimension. In a study of 165 patients receiving regular dialysis, 83 were anti-HCV positive, and anti-HCV positivity was independently associated with a lower mental component summary score on the SF-36 quality-of-life instrument, with a coefficient of –3.423 and p = 0.016. No association was found with the physical component summary score. The evidence suggests that the burden of infection may be registered more clearly in mental well-being than in a simple physical-function measure, amid the overlapping effects of dialysis, fatigue, cognitive impairment, depression, and anxiety.

Relation to Transplantation and the Volume’s Larger Argument

The significance of Messa’s contribution extends to kidney transplantation. The volume states that KDIGO recommends treatment for all HCV-positive renal-transplant candidates because life expectancy is greater in this group than in other dialysis patients, while immunosuppressive therapy increases the risk of liver-disease progression and interferon after transplantation can threaten renal-graft function. Patients on a kidney waiting list therefore require continuing surveillance rather than a single historical screening result. Those who have not been tested should undergo antibody screening with nucleic-acid confirmation in low-prevalence settings, or direct nucleic-acid testing in high-prevalence settings; patients with positive nucleic-acid tests should be placed on hold and referred for hepatological assessment and possible treatment.

This policy setting clarifies the chapter’s importance. Hepatitis C affects not only the probability of liver injury but also eligibility, timing, and safety across the transplant pathway. The preface describes the book as an international review of HCV infection, renal disease, dialysis problems, renal transplantation, and renal complications in people with HIV infection. Messa’s named position among the authors makes the dialysis patient a central clinical subject within that network of concerns: a patient whose viral status must be diagnosed precisely, whose liver disease may remain hidden, whose treatment may carry substantial toxicity, whose quality of life may deteriorate, and whose future transplant options depend on how those facts are interpreted together.

Messa is not presented through a personal biography or a dramatic narrative arc. His documented presence is that of a specialist author and institutional representative whose contribution helps assemble the book’s evidence-based account of hepatitis C in chronic kidney disease. Through the chapter credited to him, dialysis becomes more than the background against which liver disease occurs. It is the clinical environment that reshapes symptoms, alters laboratory interpretation, changes transmission risks, complicates antiviral therapy, affects mental quality of life, and turns infection status into a continuing question of survival and transplantation.